FDA Clears AI Software for Enhanced Lung Nodule Detection on Chest X-Rays
Tailored for incidental findings on chest radiographs, the qXR for Lung Nodule (qXR-LN) software utilizes artificial intelligence (AI) to help detect suspected pulmonary nodules ranging between 6 to 30 mm.
The Food and Drug Administration (FDA) has granted 510(k) clearance for the artificial intelligence (AI)-enabled qXR for Lung Nodule (qXR-LN) software, which may enhance detection of pulmonary nodules on chest X-rays.
Qure.ai, the developer of the software, said qXR-LN detects and highlights regions of suspected pulmonary nodules, ranging between 6 to 30 mm in size. Geared to diagnosing incidental findings on chest radiographs, the AI software can also be utilized as a second reader in the review of AP and PA chest radiographs, according to Qure.ai.
The company noted that one multicenter study, involving 40 sites, revealed a 94 percent AUC for qXR-LN in stand-alone detection of lung nodule detection.
“Solutions like Qure.ai's qXR-LN are a significant step towards establishing new possibilities in pulmonary imaging, particularly within oncology. The need for early-stage lung cancer detection is crucial, and tools like qXR-LN can play a significant role in the early detection of incidental nodules,” noted Vishisht Mehta, M.D., F.C.C.P., the Director of Interventional Pulmonology at the Lung Center of Nevada in Las Vegas.
FDA Clears Ultrasound AI Detection for Pleural Effusion and Consolidation
June 18th 2025The 14th FDA-cleared AI software embedded in the Exo Iris ultrasound device reportedly enables automated detection of key pulmonary findings that may facilitate detection of pneumonia and tuberculosis in seconds.
